Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10094155rdf:typepubmed:Citationlld:pubmed
pubmed-article:10094155lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:10094155lifeskim:mentionsumls-concept:C0021665lld:lifeskim
pubmed-article:10094155lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:10094155lifeskim:mentionsumls-concept:C0245891lld:lifeskim
pubmed-article:10094155lifeskim:mentionsumls-concept:C0815279lld:lifeskim
pubmed-article:10094155pubmed:issue1lld:pubmed
pubmed-article:10094155pubmed:dateCreated1999-5-25lld:pubmed
pubmed-article:10094155pubmed:abstractTextInsulin-like growth factor 1 (IGF-1) plays a critical role in CNS development. IGF-1 can block neuronal apoptosis in vitro and in vivo. IGF-1 is thought to be cleaved into des-N-(1-3)-IGF-1 and an amino terminal glycine-proline-glutamate (GPE tripeptide). Here we report a neuroprotective role for GPE tripeptide, with enhanced survival of the CA1-2 hippocampal neurons following an excitotoxic insult in vitro. Binding and displacement studies suggest uniquely distributed sites of action within the rat including the hippocampal CA1-2, pyriform cortex, amygdala, choroid plexus, blood vessels and to a lesser extent in the cortical regions. A similar pattern of binding was seen in the human. This finding could lead to new strategies to reduce neuronal death after injury and in disease.lld:pubmed
pubmed-article:10094155pubmed:languageenglld:pubmed
pubmed-article:10094155pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10094155pubmed:citationSubsetIMlld:pubmed
pubmed-article:10094155pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10094155pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10094155pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10094155pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10094155pubmed:statusMEDLINElld:pubmed
pubmed-article:10094155pubmed:monthJanlld:pubmed
pubmed-article:10094155pubmed:issn0959-4965lld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:PostCClld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:FaullR LRLlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:SkinnerS JSJlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:GluckmanP DPDlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:GattoIIlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:WilliamsC ECElld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:CuratoloLLlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:GuanJJlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:DragunowMMlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:PeetersCClld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:BenattiLLlld:pubmed
pubmed-article:10094155pubmed:authorpubmed-author:SauraJJlld:pubmed
pubmed-article:10094155pubmed:issnTypePrintlld:pubmed
pubmed-article:10094155pubmed:day18lld:pubmed
pubmed-article:10094155pubmed:volume10lld:pubmed
pubmed-article:10094155pubmed:ownerNLMlld:pubmed
pubmed-article:10094155pubmed:authorsCompleteYlld:pubmed
pubmed-article:10094155pubmed:pagination161-4lld:pubmed
pubmed-article:10094155pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:meshHeadingpubmed-meshheading:10094155...lld:pubmed
pubmed-article:10094155pubmed:year1999lld:pubmed
pubmed-article:10094155pubmed:articleTitleNeuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro.lld:pubmed
pubmed-article:10094155pubmed:affiliationDepartment of Pharmacology, School of Medicine, University of Auckland, New Zealand.lld:pubmed
pubmed-article:10094155pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10094155pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10094155lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10094155lld:pubmed